A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
for DLBCL
26 locations incl. Glendale
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT05139017·Phase 2, Phase 3·Recruiting